BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/17/2022 3:19:27 AM | Browse: 330 | Download: 1119
 |
Received |
|
2021-11-09 13:11 |
|
Peer-Review Started |
|
2021-11-09 13:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-27 08:35 |
|
Revised |
|
2022-01-13 12:01 |
|
Second Decision |
|
2022-04-19 02:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-04-22 20:25 |
|
Articles in Press |
|
2022-04-22 20:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-20 06:31 |
|
Publish the Manuscript Online |
|
2022-06-17 03:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Allergy |
| Manuscript Type |
Case Report |
| Article Title |
Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kai Liu, Jian-Feng Bao, Tao Wang, Hao Yang and Bao-Ping Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China (General Program) |
81873317 |
| the Natural Science Foundation of Zhengjiang |
LSY19H030002 |
| the Science and technology projects of Hangzhou City |
20181228Y22 |
|
| Corresponding Author |
Bao-Ping Xu, MD, Professor, Department of Critical Care Medicine, Traditional Chinese Hospital of Lu'an affiliated to Anhui University of Traditional Chinese Medicine, No. 76 Renmin Road, Lu'an 237000, Anhui Province, China. xu131406@qq.com |
| Key Words |
Camrelizumab; Anaphylactic shock; Anti-programmed cell death one antibodies; Immunotherapy; Case report |
| Core Tip |
Since its approval in 2019 by the National Drug Administration, camrelizumab (SHR-1210), a programmed cell death 1 inhibitor, is in wide clinical use as a therapeutic option for various tumor types. Until now, allergic reactions induced by camrelizumab have been rarely reported from various studies. For the first time, we report a case of camrelizumab-induced anaphylactic shock in a patient with esophageal squamous cell carcinoma. |
| Publish Date |
2022-06-17 03:19 |
| Citation |
Liu K, Bao JF, Wang T, Yang H, Xu BP. Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature. World J Clin Cases 2022; 10(18): 6198-6204 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i18/6198.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i18.6198 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
